Quality of life of patients with uterine fibroids

Abstract

BACKGROUND: Currently, there is an elevation in the incidence of uterine fibroids in increasingly younger women of reproductive age. Taking into account the current trend of late motherhood, this cohort of patients is interested in using reliable reversible contraception. Combined hormonal contraceptives meet these criteria and are able to neutralize the clinical manifestations of uterine fibroids, thereby improving the quality of life of patients. At the same time, some combined hormonal contraceptives users may experience a decrease in libido and a change in their psycho-emotional state as a manifestation of the side effects of these drugs.

AIM: The aim of this study was to assess the effect of combined hormonal contraceptives on the quality of life in patients with uterine fibroids.

MATERIALS AND METHODS: This study involved 100 patients with uterine fibroids (F3–F6 according to classification of the International Federation of Gynecology and Obstetrics, without indications for surgical treatment) and 30 healthy women aged 18 to 49 years. For contraceptive purposes, 40 participants with uterine fibroids used combined hormonal contraceptives containing ethinyl estradiol (group I) and 60 patients with uterine fibroids did not use any medications (group II). The following validated questionnaires were used for patients with uterine fibroids — at the beginning and after 6 months, and for healthy women in the control group (group III) — once upon entry into the study: Short Form-36, Female Sexual Function Index, and Beck Depression Inventory. A comparative statistical analysis of the studied parameters over time was carried out.

RESULTS: At baseline, a lower quality of life was noted in patients with uterine fibroids compared to the control group (Short Form-36): 94 ± 6 vs 102 ± 11 points, respectively (p < 0.05). After 6 months, patients in group I showed positive dynamics with increasing in the total Short Form-36 from 95 ± 4 to 98 ± 5 points (p < 0.05) compared to patients in group II: 94 ± 6 and 93 ± 5 points (p > 0.05). We revealed no changes in the Female Sexual Function Index in the study groups — at baseline: 24.8 ± 8.9 (group I), 23.9 ± 9.5 (group II), and 27.8 ± 4.7 (group III); and after 6 months: 26.4 ± 9.2 (group I) and 23.9 ± 10.0 (group II) (p > 0.05 for all comparisons). When comparing the results of a questionnaire on the Beck scale, no dynamics were determined in patients with uterine fibroids, including those who used combined hormonal contraceptives.

CONCLUSIONS: The study demonstrated a lower quality of life in patients with uterine fibroids compared to healthy women and an improved quality of life in patients with uterine fibroids using combined hormonal contraceptives. We showed no negative effects of contraceptive drugs on libido and emotional state in women with uterine fibroids who used combined hormonal contraceptives for 6 months.

Keywords

uterine fibroids / combined hormonal contraceptives / quality of life / sexual function / depression

References

[1] Novik AA, Ionova TA. Guidelines for quality of life research in medicine. 2nd ed. YuL Shevchenko editor. Moscow: OLMA Media Group; 2007. (In Russ.) EDN: QLOWXD

[2] Новик А.А., Ионова Т.А. Руководство по исследованию качества жизни в медицине. 2-е изд. / под ред. Ю.Л. Шевченко. Москва: ОЛМА Медиа Групп, 2007. EDN: QLOWXD

[3] Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015 [cited 21.09.2023]. Available from: https://iris.who.int/bitstream/handle/10665/181468/9789241549158_eng.pdf?sequence=9

[4] Медицинские критерии приемлемости для использования методов контрацепции. ВОЗ. 5-е изд. Женева: ВОЗ, 2015. Режим доступа: https://iris.who.int/bitstream/handle/10665/326788/9789289052689-rus.pdf?sequence=3. Дата обращения: 21.09.2023.

[5] Federal State Budgetary Institution National Medical Research Center of Obstetrics, Gynecology and Perinatology named after. Academician V.I. Kulakov Ministry of Health of the Russian Federation, Russian Society of Obstetricians and Gynecologists, Russian Society for Contraception. National medical criteria for the acceptability of contraceptive methods. Adapted document “Medical eligibility criteria for the use of WHO contraceptive methods. 5th ed., 2015”. Sukhikh GT, Prilepskaya VN, editors. Moscow; 2023 [cited 21.09.2023]. Available from: https://phlebounion.ru/files/uploads/News/files/2023%20Национальные%20критерии%20приемлемости%20контрацепции%202023.pdf

[6] ФГБУ НМИЦ акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Министерства Здравоохранения РФ, Российское общество акушеров-гинекологов, Российское общество по контрацепции. Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ. 5-е изд., 2015» / под ред. Г.Т. Сухих, В.Н. Прилепской. Москва, 2023. Режим доступа: https://phlebounion.ru/files/uploads/News/files/2023%20Национальные%20критерии%20приемлемости%20контрацепции%202023.pdf. Дата обращения: 21.09.2023

[7] Burrows LJ, Basha M, Goldstein AT. The effects of hormonal contraceptives on female sexuality: a review. J Sex Med. 2012;9(9):2213–2223. doi: 10.1111/j.1743-6109.2012.02848.x

[8] Burrows L.J., Basha M., Goldstein A.T. The effects of hormonal contraceptives on female sexuality: a review // J Sex Med. 2012. Vol. 9, N. 9. P. 2213–2223. doi: 10.1111/j.1743-6109.2012.02848.x

[9] Lundin C, Danielsson KG, Bixo M, et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle – A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology. 2017;76:135–143. doi: 10.1016/j.psyneuen.2016.11.033

[10] Lundin C., Danielsson K.G., Bixo M., et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle – A double-blind, placebo-controlled randomized trial // Psychoneuroendocrinology. 2017. Vol. 76. P. 135–143. doi: 10.1016/j.psyneuen.2016.11.033

[11] Lundin C, Wikman A, Lampa E, et al. There is on association between combined oral contraceptives and depression: a Swedish register-based cohort study. BJOG. 2022;129(6):917–925. doi: 10.1111/1471-0528.17028

[12] Lundin C., Wikman A., Lampa E., et al. There is on association between combined oral contraceptives and depression: a Swedish register-based cohort study // BJOG. 2022. Vol. 129, N. 6. P. 917–925. doi: 10.1111/1471-0528.17028

[13] Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393–408. doi: 10.1002/ijgo.12666

[14] Munro M.G., Critchley H.O.D., Fraser I.S.; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions // Int J Gynaecol Obstet. 2018. Vol. 143, N. 3. P. 393–408. doi: 10.1002/ijgo.12666

[15] Instructions for processing data obtained using the SF-36 questionnaire [Internet] [cited 12.01.2024]. Available from: http://therapy.irkutsk.ru/doc/sf36a.pdf (In Russ.)

[16] Инструкция по обработке данных, полученных с помощью опросника SF-36. [Internet]. Режим доступа: http://therapy.irkutsk.ru/doc/sf36a.pdf. Дата обращения: 12.01.2024.

[17] Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(1):191–208. doi: 10.1080/009262300278597

[18] Rosen R., Brown C., Heiman J. et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function // J Sex Marital Ther. 2000. Vol. 26, N. 1. P. 191–208. doi: 10.1080/009262300278597

[19] Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004

[20] Beck A.T., Ward C.H., Mendelson M., et al. An inventory for measuring depression // Arch Gen Psychiatry. 1961. Vol. 4. P. 561–571. doi: 10.1001/archpsyc.1961.01710120031004

[21] Ministry of Health of the Russian Federation, LLC “Russian Society of Obstetricians and Gynecologists” (ROAG). Uterine fibroids. Clinical guidelines. Moscow; 2020 [cited 12.01.2024]. Available from: https://minzdravri.ru/wp-content/uploads/2020/12/mioma-matki.pdf (In Russ).

[22] Министерство здравоохранения Российской федерации, ООО «Российское общество акушеров-гинекологов» (РОАГ). Миома матки. Клинические рекомендации Москва, 2020. Режим доступа: https://minzdravri.ru/wp-content/uploads/2020/12/mioma-matki.pdf. Дата обращения: 12.01.2024

[23] Williams VS, Jones G, Mauskopf J, et al. Uterine fibroids: a review of health-related quality of life assessment. J Womens Health. 2006;15(7):818–829. doi: 10.1089/jwh.2006.15.818

[24] Williams V.S., Jones G., Mauskopf J., et al. Uterine fibroids: a review of health-related quality of life assessment // J Womens Health. 2006. Vol. 15, N. 7. P. 818–829. doi: 10.1089/jwh.2006.15.818

[25] Dilek S, Ertunc D, Tok EC, et al. The effect of myomectomy on health-related quality of life of women with myoma uteri. J Obstet Gynaecol Res. 2010;36(2):364–369. doi: 10.1111/j.1447-0756.2009.01149.x

[26] Dilek S., Ertunc D., Tok E.C., et al. The effect of myomectomy on health-related quality of life of women with myoma uteri // J Obstet Gynaecol Res. 2010. Vol. 36, N. 2. P. 364–369. doi: 10.1111/j.1447-0756.2009.01149.x

[27] Davis AR, Castaño PM. Oral contraceptives and libido in women. Annu Rev Sex Res. 2004;15:297–320. doi: 10.1201/b14618-40

[28] Davis A.R., Castaño P.M. Oral contraceptives and libido in women // Annu Rev Sex Res. 2004. Vol. 15. P. 297–320. doi: 10.1201/b14618-40

[29] Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review. Eur J Contracept Reprod Health Care. 2013;18(1):27–43. doi: 10.3109/13625187.2012.728643

[30] Pastor Z., Holla K., Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review // Eur J Contracept Reprod Health Care. 2013. Vol. 18, N. 1. P. 27–43. doi: 10.3109/13625187.2012.728643

[31] Elaut E, Buysse A, De Sutter P, et al. Cycle-related changes in mood, sexual desire, and sexual activity in oral contraception-using and nonhormonal-contraception-using couples. J Sex Res. 2016;53(1):125–136. doi: 10.1080/00224499.2014.976780

[32] Elaut E., Buysse A., De Sutter P., et al. Cycle-related changes in mood, sexual desire, and sexual activity in oral contraception-using and nonhormonal-contraception-using couples // J Sex Res. 2016. Vol. 53, N. 1. P. 125–136. doi: 10.1080/00224499.2014.976780

[33] Smith NK, Jozkowski KN, Sanders SA. Hormonal contraception and female pain, orgasm and sexual pleasure. J Sex Med. 2014;11(2):462–470. doi: 10.1111/jsm.12409

[34] Smith N.K., Jozkowski K.N., Sanders S.A. Hormonal contraception and female pain, orgasm and sexual pleasure // J Sex Med. 2014. Vol. 11, N. 2. P. 462–470. doi: 10.1111/jsm.12409

[35] Lethaby A, Wise MR, Weterings MA, et al. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2(2). doi: 10.1002/14651858.CD000154.pub3

[36] Lethaby A., Wise M.R., Weterings M.A., et al. Combined hormonal contraceptives for heavy menstrual bleeding // Cochrane Database Syst Rev. 2019. Vol. 2, N. 2. doi: 10.1002/14651858.CD000154.pub3

[37] Scheuringer A, Lundin C, Derntl B, et al. Use of an estradiol-based combined oral contraceptives has no influence on attentional bias or depressive symptoms in healthy women. Psychoneuroendocrinology. 2020;113. doi: 10.1016/j.psyneuen.2019.104544

[38] Scheuringer A., Lundin C., Derntl B., et al. Use of an estradiol-based combined oral contraceptives has no influence on attentional bias or depressive symptoms in healthy women // Psychoneuroendocrinology. 2020. Vol. 113. doi: 10.1016/j.psyneuen.2019.104544

[39] Pagano PH, Zapata BL, Berry-Bibee NE, et al. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Contraception. 2016;94(6):641–649. doi: 10.1016/j.contraception.2016.06.012

[40] Pagano P.H., Zapata B.L., Berry-Bibee N.E., et al. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review // Contraception. 2016. Vol. 94, N. 6. P. 641–649. doi: 10.1016/j.contraception.2016.06.012

RIGHTS & PERMISSIONS

Eсо-Vector